NCT06763965 2026-03-23
Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1/2 Enrolling by invitation
Clinical Trials
20 trialsNCT07126990 2026-03-23
Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1/2 Enrolling by invitation
NCT05741242 2026-01-15
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Jaime Leandro Foundation for Therapeutic Cancer Vaccines
Phase 1/2 Enrolling by invitation
NCT05570994 2026-01-08
177Lu-HTK03170 in mCRPC With PSMA Positive Disease
British Columbia Cancer Agency
Phase 1/2 Enrolling by invitation
NCT06603987 2025-11-19
Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
Stella Pharma Corporation
Phase 1/2 Enrolling by invitation
NCT07210047 2025-10-07
Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients
HuniLife Biotechnology, Inc.
Phase 1/2 Enrolling by invitation
NCT05893654 2025-09-15
MELCOM
Hospital das ClÃnicas de Ribeirão Preto
Phase 1/2 Enrolling by invitation
NCT06936527 2025-09-03
XS-03-II201
NovaOnco Therapeutics Co., Ltd.
Phase 1/2 Enrolling by invitation
NCT05385861 2025-08-15
Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET
National Health Research Institutes, Taiwan
Phase 1/2 Enrolling by invitation
NCT06027879 2025-06-25
Gamma Capture
University of Pittsburgh
Phase 1/2 Enrolling by invitation
NCT06992687 2025-05-28
A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2 Enrolling by invitation
NCT06768268 2025-04-16
ICGMV
National Taiwan University Hospital
Phase 1/2 Enrolling by invitation
NCT06690216 2025-03-30
PD-L1-PET
Shandong Cancer Hospital and Institute
Phase 1/2 Enrolling by invitation
NCT06890871 2025-03-24
Radiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study
Zhongnan Hospital
Phase 1/2 Enrolling by invitation
NCT04145375 2025-03-19
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
Zenith Epigenetics
Phase 1/2 Enrolling by invitation
NCT01868490 2025-02-10
The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells
Siriraj Hospital
Phase 1/2 Enrolling by invitation
NCT06762431 2025-01-07
VTB-CLL002
Vitebsk Regional Clinical Cancer Centre
Phase 1/2 Enrolling by invitation
NCT00900497 2024-12-04
A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers
South Florida Bone Marrow/Stem Cell Transplant Institute
Phase 1/2 Enrolling by invitation
NCT05865925 2024-04-25
Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors
Luye Pharma Group Ltd.
Phase 1/2 Enrolling by invitation
NCT06303583 2024-03-12
CRIS
Zhejiang Cancer Hospital
Phase 1/2 Enrolling by invitation